Hybrid assays are advanced analytical tools that combine the strengths of immunoassays and mass spectrometry to enable precise protein bioanalysis of both therapeutic biologics and endogenous biomarkers. In this insight brief, we explore what hybrid assays are, how they are applied in drug development and biomarker discovery, the analytical and regulatory challenges they present, and the future potential of this powerful technology. Learn how hybrid bioanalytical platforms are transforming the landscape of quantitative protein analysis in modern biopharma.
Complete the form below to access this insight brief
Related Insights
ADME Services
Accelerating your drug discovery, preclinical and clinical programs
Developing Assays for Novel Drugs
Current science regarding hybrid assays, why they are considered the next "big thing," the technical challenges, and the regulatory impact of these assays.
Bioanalysis for Immuno Oncology with Mike Brown
I-O clinical development podcast series
High Throughput ADME Testing
Minimizing turnaround time for ADME assays
ADME Services
Accelerating your drug discovery, preclinical and clinical programs with ADME services
Assay Development for Large-Scale Clinical Studies
Bioanalytical expertise to support large-scale, international studies
Early Hit-to-Lead ADME Screening Bundle
Bundled Screening Assays to Accelerate Candidate Selection in Drug Discovery
High Throughput ADME Screening Services
Capabilities that accelerate preclinical studies
IND-Enabling Bundle of In Vitro Assays to Assess Drug-Drug Interaction Risk
DDI Fact Sheet
In vitro ADME, LC-MS/MS bioanalysis and metabolite identification service list
Services to support your In Vitro ADME development needs
